{"id":1623,"date":"2018-12-05T10:30:00","date_gmt":"2018-12-05T10:30:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/program-till-oncopeptides-kapitalmarknadsdag-den-14-december-2018\/"},"modified":"2026-02-23T13:18:33","modified_gmt":"2026-02-23T13:18:33","slug":"program-till-oncopeptides-kapitalmarknadsdag-den-14-december-2018","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/program-till-oncopeptides-kapitalmarknadsdag-den-14-december-2018\/","title":{"rendered":"Program till Oncopeptides kapitalmarknadsdag den 14 december 2018"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Stockholm &#8211; 5 december 2018 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) har tidigare annonserat att de kommer att h&aring;lla en kapitalmarknadsdag i New York. Programmet &auml;r nu tillg&auml;ngligt nedan och p&aring; f&ouml;retagets hemsida: www.oncopeptides.com \/ Investerare &amp; media \/ Kalendarium. Kapitalmarknadsdagen kommer att webcastas.<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">+&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;+<br \/>|Tid: Registrering och frukost: 08.00 &#8211; 08.30&nbsp; |&nbsp; Presentation 8.30 &#8211; 11.00 ET|<br \/>|Plats: The Maxwell Hotel, 541 Lexington Avenue, New York.                    |<br \/>+&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;+<\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides Capital Markets Day Program<\/p>\n<p class=\"mfn-wp-retain\">8.30 &#8211; 09.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Introduction to Oncopeptides including a Clinical Trials Overview<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jakob Lindberg, CEO of Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">9.00 &#8211; 09.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HORIZON and ANCHOR Trials Data Update<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Professor Paul G Richardson, Dana-Farber Cancer Institute&nbsp;<\/p>\n<p class=\"mfn-wp-retain\">9.45 &#8211; 9.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Short Break<\/p>\n<p class=\"mfn-wp-retain\">09.50 &#8211; 10.10&nbsp;&nbsp;&nbsp; The Evolving Myeloma Treatment Landscape and the Position of<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Melflufen<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paula Boultbee, CCO at Oncopeptides&nbsp;<\/p>\n<p class=\"mfn-wp-retain\">10.10 &#8211; 10.40&nbsp;&nbsp;&nbsp; Panel discussion and Q&amp;A<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Professor Paul G Richardson, Dana-Farber Cancer Institute&nbsp;<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jakob Lindberg, CEO of Oncopeptides<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Christian Jacques, MD, MSc, EVP Clinical Strategy and Chief Scientific Officer<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paula Boultbee, CCO at Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">10.40 &#8211; 11.00 &nbsp; Summary and Conclusions<br \/>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Jakob Lindberg, CEO of Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Registrering f&ouml;r investerare och analytiker: RSVP till Alan Lada p&aring; alada@troutgroup.com<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information, kontakta: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<\/p>\n<p class=\"mfn-wp-retain\">Rein Piir, Head of Investor Relations f&ouml;r Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<br \/>Mobil: +46 708 53 72 92<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 5 december 2018 kl. 11.30 CET.<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<\/p>\n<p class=\"mfn-wp-retain\">Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag som utvecklar l&auml;kemedel f&ouml;r behandling av cancer. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen (Ygalo&reg;), en peptidl&auml;nkad alkylator, tillh&ouml;rande en ny l&auml;kemedelsklass kallad Peptidase Enhanced Compounds. Melflufen &auml;r avsedd f&ouml;r en effektiv behandling av hematologiska cancersjukdomar, och d&aring; s&auml;rskilt multipelt myelom. M&aring;let med det kliniska utvecklingsprogrammet f&ouml;r melflufen &auml;r att visa b&auml;ttre behandlingsresultat j&auml;mf&ouml;rt med etablerade alternativ vid behandling av patienter med multipelt myelom. Melflufen kan potentiellt ge behandlande l&auml;kare ett nytt l&auml;kemedel f&ouml;r patienter med denna sv&aring;rbehandlade cancersjukdom.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2692969%2F958136.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2692969%2F958136.pdf&type=jpg\"><\/span>PDF<\/a><\/div><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FPublic%2F15404%2F2692969%2Fb8889271703f12fd.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FPublic%2F15404%2F2692969%2Fb8889271703f12fd.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm &#8211; 5 december 2018 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO) har tidigare annonserat att de kommer att h&aring;lla en kapitalmarknadsdag i New York. Programmet &auml;r nu tillg&auml;ngligt nedan och p&aring; f&ouml;retagets hemsida: www.oncopeptides.com \/ Investerare &amp; media \/ Kalendarium. Kapitalmarknadsdagen kommer att webcastas. +&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8211;+|Tid: Registrering och frukost: 08.00 &#8211; 08.30&nbsp; |&nbsp; Presentation 8.30 &#8211; [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1623","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1623"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1623"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}